DVT Prevention

  • About PlasmaFlow
    • The PlasmaFlow is intended to be an easy to use sequential compression system, prescribed by a physician, for use in the home or clinical setting to help prevent the onset of DVT in patients by stimulating blood flow in the extremities (stimulating muscle contractions).

      This device can be used to:

      • Aid in the prevention of DVT
      • Enhance blood circulation
      • Diminish post-operative pain and swelling
      • Reduce wound healing time
      • Aid in the treatment and healing of: stasis dermatitis, venous stasis ulcers, arterial and diabetic leg ulcers, chronic venous insufficiency and reduction of edema in the lower limbs.

      Portable, lightweight and tubeless
      Long lasting re-chargeable battery. Up to 10 hours of use on one charge
      2 Modes: Slow inflation and Step-Up Technology which allows the unit to increase pressure in slower increments
      2 LCD screens to monitor usage and pressure

      • Lowers Risk of Venous Thromboembolism (VTE): PlasmaFlow lowers incidence of VTE after major orthopedic surgery compared to pharmacological prophylaxis. VTE is the leading factor for hospital readmission following major orthopedic surgery and the most common preventable cause of hospital death.
      • Provides Possible Alternative to Anticoagulants: PlasmaFlow offers physicians another option to help tailor preventative care to patient risk and provides an alternative for patients contraindicated for anticoagulants.
      • Provides Convenient Home Therapy: As hospital stays continue to shorten, PlasmaFlow provides a solution for patients to take home and keep. This allows facilities to offer mechanical DVT prophylaxis for the 2-3 weeks patients need it most, without the hassle of renting or servicing equipment.
      • Lowers Total Cost: Bundled payment of care initiatives are driving single payment for an orthopedic episode within 30 days of surgery, including costly DVT readmissions. By reducing DVT-related expenses and potentially reducing costs for anticoagulant regimes or compression device rental programs, PlasmaFlow helps reduce the total cost of the episode.
  • Why is PlasmaFlow Medically Necessary
    • The critical post discharge period due to the medical necessity of increasing blood circulation and decreasing postoperative pain, swelling and inflammation. PlasmaFlow mobile compression system received FDA clearance and has proven clinical studies that show it is an effective non pharmacologic therapy for enhancement of blood circulation and or DVT Management. Clinical evidence has shown the PlasmaFlow mobile compression system to be as effective as low molecular weight heparins LMWH and to eliminate the anticoagulants serious bleeding complications. Significant published data is available on the incidents of DVT/PE, the effectiveness of various prophylactic techniques and the risks of hemorrhage when heparin is used, all of which provide positive and compelling evidence in support for the use of intermittent compression devices in VTE prevention.


      The surgeons has prescribed the above system and certify that the PlasmaFlow mobile compression system device and supplies are medically necessary for the treatment of his patient’s care. The doctor has found that the PlasmaFlow mobile compression system improves the healing time and provides reduction of complications following orthopedic surgery. Recovery is quicker and subsequent physical therapy is more effective. The foregoing is per consensus from the guidelines for VTE Prophylaxis from the ACCP (American College of Chest Physicians); recommendations from AAOS (American Academy of Orthopedic Surgeons); and SCIP (Surgical Care Improvement Program).

      Featured Clinical Study – Attached

      1. Journal of Arthroplasty 2017 – The DVT rate for the post discharge protocol of Aspirin and Portable Mechanical Compression therapy group was 0%. The DVT rate for the post discharge protocol of just Aspirin group was 23.1%

      Additional attached are the clinical studies.

      1. JBJS Study – Sequential devices (PlasmaFlow) are clinically equivalent to decrease risk of Blood Clots instead of using a pharmacologic option which may increase your bleed risks.
      2. AAOS – Mechanical Prophylaxis dissertation. 895 Page AAOS but specifically highlighted mechanical.
      3. AAOS Clot formation – 2009 – The risk of development is two to five days after surgery; a second peak development period occurs about 10 days after surgery, after most patients have been discharged from the hospital.


      Other major indications for PlasmaFlow include
      • Moderate to high risk DVT medical patients that are being discharged from the hospital – CHF, COPD, Pneumonia, Sepsis, CVA
      • Patients that go to extended care facilities because most facilities do not carry SCDs
      • Spine and Neurosurgery – where anticoagulation is contraindicated
      • Metastatic cancer patients should be on LovenoxÒ for DVT prophylaxis, PlasmaFlow presents a multi-modality approach
      • Non-Ambulatory hospital patients
      • OBGYN – C sections and high risk pregnancies
      • GI Bleed patients with high risk of DVT
      • Patients with a low platelet count

      Interesting Facts of Blood Clots https://www.stoptheclot.org/

      The Public Health Burden Associated with Blood Clots

      Blood clots affect many people — people from all walks of life — and no one person is any less important than another. It’s difficult to look at the numbers below, and not think of the individuals — their families, their friends — and not ask oneself, “Could I be at risk for a blood clot?” The answer most certainly is, “Yes, anyone can affected by blood clots.” Blood clots do not discriminate.

      Tragically, too many lives are affected by blood clots, and too many lives are lost because public awareness about life-threatening blood clots is so low. Study after study has shown that fewer than 1 in 4 people have any recognition of blood clots or their signs and symptoms.


      On Average, 274 People Die Every Day from Blood Clots

      — 107 to 130 cases of potentially deadly blood clots occurred each year per 100,000 Caucasian individuals from 1985 through 2002. This translates into about 1 to 3 cases per 1,000 people.
      — 250,000 cases of potentially deadly blood clots, such as deep vein thrombosis or DVT, occurred each year between 1966 through 1990.
      — 900,000 cases per year are now suggested by recent scientific modeling and public health statistics.
      — 100,000 to 300,000 deaths from blood clots occur each year, which is greater than the total number of people who lose their lives each year to AIDS, breast cancer, and motor vehicle crashes combined.
      — 600,000 non-fatal cases of deadly blood clots occur each year, of which 40% are blood clots in the lungs and 60% are blood clots in the legs
      — 547,596 hospitalizations due to blood clots occurred from 2007 – 2009.

      On average, one person dies every six minutes from a blood clot.
      Don’t be one of them. Blood Clots Can Be Prevented.
      Understand the risks. Know the signs & symptoms.
      Provoked Blood Clots (70% of all patients)
      • Associated with known risk factors
      • Surgery, hospital, cancer, medical illness, genetic
      • Risk factors may be continuing
      • If risk factor transient, 2% per year recurrence after 3 months of anticoagulant therapy
      Unprovoked (30% of all patients)
      • Absence of identifiable risk factor
      • Also called “idiopathic”
      • 7% to 11% per year recurrence for DVT or PE if anticoagulant therapy stopped after 3, 6,12 or 24 months
Serving the orthotic and prosthetic community for over 35 years.
Servicing all local hospitals